Last reviewed · How we verify
Seqirus QIV
Seqirus QIV is a quadrivalent influenza vaccine that stimulates the body's immune system to produce antibodies against four different influenza viruses.
Seqirus QIV is a quadrivalent influenza vaccine that stimulates the body's immune system to produce antibodies against four different influenza viruses. Used for Prevention of influenza disease caused by four different strains of the influenza virus.
At a glance
| Generic name | Seqirus QIV |
|---|---|
| Sponsor | Seqirus |
| Drug class | inactivated vaccine |
| Modality | Biologic |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
This vaccine works by introducing small, harmless pieces of the influenza virus to the body, which triggers an immune response and helps the body develop immunity to the virus. The vaccine contains four different strains of the influenza virus, which are updated annually to match the most common strains expected to circulate during the upcoming flu season.
Approved indications
- Prevention of influenza disease caused by four different strains of the influenza virus
Common side effects
- Pain, redness, or swelling at the injection site
- Fatigue
- Headache
Key clinical trials
- Clinical Trial to Evaluate the Immunogenicity of an Adjuvanted Influenza Vaccine Among HCP (PHASE3)
- Efficacy Study With QIVc in Pediatric Subjects (PHASE3)
- A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age. (PHASE3)
- A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |